LAVA Therapeutics N.V. Ordinary Shares
Symbol: LVTX (NASDAQ)
1.62
▼ (-0.61%) -0.010
Company Description:
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
Key Stats
- Today's Open: $1.61
- Today's High: $1.635
- Today's Low: $1.585
- Today's Volume: 85.91K
- Yesterday Close: $1.63
- Yesterday High: $1.64
- Yesterday Low: $1.45
- Yesterday Volume: 2.56M
- Last Min Volume: 1
- Last Min High: $1.62
- Last Min Low: $1.61
- Last Min VWAP: $1.611
Company Profile
- Name: LAVA Therapeutics N.V. Ordinary Shares
- Website: https://www.lavatherapeutics.com
- Listed Date: 2021-03-25
- Location: UTRECHT, P7
- Market Status: Active
- CIK Number: 0001840748
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $38.67M
- Round Lot: 100
- Outstanding Shares: 26.31M
- Asset Type: CS
RECENT FILINGS FOR LVTX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-22 | SCHEDULE 13D/A | View |
| 2025-10-20 | 4 | View |
| 2025-10-17 | SCHEDULE 13D/A | View |
| 2025-10-17 | DEFR14A | View |
| 2025-10-17 | SC 14D9/A | View |
| 2025-10-17 | SC TO-T/A | View |
| 2025-10-17 | DEFA14A | View |
| 2025-10-17 | 8-K | View |
| 2025-10-15 | 4 | View |
| 2025-10-14 | SCHEDULE 13D/A | View |
| 2025-10-10 | 4 | View |
| 2025-10-02 | SC 14D9/A | View |
| 2025-10-02 | DEFA14A | View |
| 2025-10-02 | 8-K | View |
| 2025-10-02 | SC TO-T/A | View |
| 2025-09-30 | DEFA14A | View |
| 2025-09-30 | 8-K | View |
| 2025-09-26 | SCHEDULE 13G | View |
| 2025-09-23 | SCHEDULE 13D/A | View |
| 2025-09-23 | 4 | View |
Latest News on LVTX